Earnings analysis · 10-Q
SKYD earnings analysis
Filed November 9, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not contain the consolidated income statement, balance sheet, cash-flow statement, or segment tables, so revenue, margins, EPS, cash flow, and working-capital trends cannot be verified…
Read full summary
The supplied 10-Q extract does not contain the consolidated income statement, balance sheet, cash-flow statement, or segment tables, so revenue, margins, EPS, cash flow, and working-capital trends cannot be verified from the filing text provided. The principal disclosed change is the WBD Merger financing: $72.1 billion of additional debt was incurred or assumed after September 30, 2026, with approximately $14.5 billion of variable-rate borrowings exposed to a $145 million annual interest-cost sensitivity per 1.00% rate move. New merger-related operating restrictions and approximately 470.7 million Warrants add substantial execution, leverage, and dilution risks.
What stood out
-
Interest-rate exposure is quantified
The filing quantifies the post-merger financing exposure: variable-rate borrowings were approximately $14.5 billion as of October 6, 2026, and the company identifies a $145 million annual interest-expense sensitivity for each 1.00% benchmark-rate change.
-
Euro financing exposure is hedged
The company disclosed hedging arrangements for its euro exposure, including fixed-for-fixed cross-currency swaps for euro-denominated second-lien notes and designation of the Euro Term B-1 Loans as net-investment hedges.
-
Controls remained effective
The company’s principal executive and financial officers concluded that disclosure controls were effective as of the period end, and reported no material change in internal control over financial reporting during the last fiscal quarter.
-
Regulatory obligations are specified
The States Consent Decree provides defined operating parameters, including annual U.S. film releases of at least 30 to 32 films, a minimum $300 million increase in annual U.S. production spending versus combined 2025 levels, and $9.5 million of annual workforce and arts funding.
What to watch
-
Merger substantially increases leverage
The company incurred or assumed $72.1 billion of additional aggregate principal debt in connection with the WBD Merger, on top of $16.29 billion of debt outstanding at September 30, 2026. The filing warns that insufficient cash flow could require reduced content spending, delayed investment, asset sales, or restructuring/refinancing.
-
Consent decree may constrain operations
The States Consent Decree imposes a five-year commitment period and requires, among other terms, at least 30 to 32 U.S. films annually and $300 million of additional annual U.S. production spending. A film shortfall could trigger a $30 million payment per film and potential divestiture of Miramax Studios or certain cable networks.
-
Warrants create dilution risk
The company issued approximately 470.7 million Warrants, each initially exercisable for one Class B share; full physical settlement would add approximately 470.7 million shares, or about 9% of Class B shares outstanding as of November 4, 2026. The initial physical-settlement exercise price is $12.00 per share, creating dilution and potential stock-price pressure.
Management's outlook
The supplied 10-Q extract does not include quantitative revenue or EPS guidance. The filing states that the WBD Merger-related debt and financing transactions occurred after September 30, 2026; prior outlook commentary was provided in the November 9, 2026 8-K rather than in the supplied 10-Q extract.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.